NEW YORK, NY - (NewMediaWire) - June 09, 2020 - Following its recent announcement of a new treatment designed to help relieve symptoms of cold and flu, Rapid Nutrition (RAP:SW, OTCQB:RPNRF) has been awarded an Innovation Connections grant to further develop and commercialize the formula. Sponsored by the Australian government, the grant will facilitate a partnership between Rapid Nutrition and one of Australia’s leading universities for ongoing clinical trials.
A natural healthcare company focused on sports nutrition, diet management and life sciences products with extensive worldwide distribution, Rapid Nutrition has already undergone independent testing at two laboratories for the innovative formula and an innovation patent has been successfully filed.
The Innovation Connections grant helps businesses in growth sectors, including food and agribusiness, medical technologies and pharmaceuticals, further understand their research needs, connect with the research sector and fund collaborative research projects with the aim of developing a new idea with commercial potential.
“The Innovation Connections grant is a tremendous recognition from the Australian government and a terrific step forward in launching this new therapy,” said Rapid Nutrition CEO Simon St. Ledger. “This new partnership will help us further explore the multiple uses of Azurene and the potential for relief of both the common cold and flu.”
Azurene is the product of several years of research, including in-vitro testing, scholarly literature and continuing clinical trials ahead of product launch. The antioxidant helps to reduce free radicals in the body and is traditionally used in European herbal medicine to help reduce the severity of symptoms of common colds and flu.
About Rapid Nutrition
Rapid Nutrition is a natural healthcare company focused on the research, development and production of a range of life science products. The company was established based on its successful and proven weight loss supplement range which is exported worldwide and now offers consumers a growing range of health and well-being solutions to meet existing and emerging societal health concerns, as well as a providing a number of wider services to the life sciences industry. For more information, please visit http://rnplc.com
Investor Relations Contact:
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Rapid PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning of article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act ('Rule 12g3-2(b)') permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).